ECSP24032624A - Composición farmacéutica de sepiapterina - Google Patents

Composición farmacéutica de sepiapterina

Info

Publication number
ECSP24032624A
ECSP24032624A ECSENADI202432624A ECDI202432624A ECSP24032624A EC SP24032624 A ECSP24032624 A EC SP24032624A EC SENADI202432624 A ECSENADI202432624 A EC SENADI202432624A EC DI202432624 A ECDI202432624 A EC DI202432624A EC SP24032624 A ECSP24032624 A EC SP24032624A
Authority
EC
Ecuador
Prior art keywords
sepiapterin
pharmaceutical composition
palatability
stability
discloses
Prior art date
Application number
ECSENADI202432624A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP24032624A publication Critical patent/ECSP24032624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención revela una composición farmacéutica de sepiapterina con procesabilidad, estabilidad, y palatabilidad mejoradas.
ECSENADI202432624A 2021-09-29 2024-04-26 Composición farmacéutica de sepiapterina ECSP24032624A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163250167P 2021-09-29 2021-09-29

Publications (1)

Publication Number Publication Date
ECSP24032624A true ECSP24032624A (es) 2024-05-31

Family

ID=84357981

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202432624A ECSP24032624A (es) 2021-09-29 2024-04-26 Composición farmacéutica de sepiapterina

Country Status (17)

Country Link
US (1) US20250041305A1 (es)
EP (1) EP4408401A1 (es)
JP (1) JP2024536281A (es)
KR (1) KR20240064728A (es)
CN (1) CN118317768A (es)
AR (1) AR127191A1 (es)
AU (1) AU2022354887A1 (es)
CA (1) CA3232498A1 (es)
CL (1) CL2024000892A1 (es)
CO (1) CO2024005271A2 (es)
CR (1) CR20240172A (es)
EC (1) ECSP24032624A (es)
IL (1) IL311716A (es)
MX (1) MX2024003909A (es)
PE (1) PE20241579A1 (es)
TW (1) TW202329974A (es)
WO (1) WO2023055923A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241254A1 (en) * 2007-01-02 2008-10-02 Suryakant Navale Pharmaceutical composition comprising atovaquone particles
KR20100051667A (ko) * 2007-07-27 2010-05-17 씨아이피엘에이 엘티디. 약제학적 조성물 및 그의 제조방법
AU2009287462B2 (en) * 2008-09-30 2011-10-06 Arelac, Inc. CO2-sequestering formed building materials
CA2828685C (en) * 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.

Also Published As

Publication number Publication date
CR20240172A (es) 2024-06-06
EP4408401A1 (en) 2024-08-07
MX2024003909A (es) 2024-06-28
WO2023055923A1 (en) 2023-04-06
JP2024536281A (ja) 2024-10-04
CL2024000892A1 (es) 2024-09-13
TW202329974A (zh) 2023-08-01
CO2024005271A2 (es) 2024-06-27
US20250041305A1 (en) 2025-02-06
AU2022354887A1 (en) 2024-04-04
AR127191A1 (es) 2023-12-27
PE20241579A1 (es) 2024-08-01
CN118317768A (zh) 2024-07-09
KR20240064728A (ko) 2024-05-13
IL311716A (en) 2024-05-01
CA3232498A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CO2024005271A2 (es) Composición farmacéutica de sepiapterina
EP4332105A4 (en) PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
CL2023002787A1 (es) Compuestos a base de indazol y métodos de uso asociados.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
CR20200342A (es) Composiciones de edb que se dirigen a il-12
EA202092909A1 (ru) Новый бензодиазепин, его производные и применение
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
JOP20250052A1 (ar) مركبات حلقية كبرى، وتركيبات، وطرق استخدامها
BR112022025068A2 (pt) Formas de estado sólido de ciantraniliprole
JOP20190108B1 (ar) تركيبات صيدلانية
EA202191180A1 (ru) Производные конденсированного гетероциклического бензодиазепина и их применение
MX394833B (es) Formulaciones con mejora de la estabilidad.
CL2024000321A1 (es) Antagonistas de lpar1 y usos de estos
BR112022016359A2 (pt) Formas cristalinas de um composto farmacêutico
JOP20190159B1 (ar) توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
IL285805A (en) Quinazolinone compounds, compositions comprising same and uses thereof
MX2024007305A (es) Una composicion farmaceutica estable de liberacion prolongada de clozapina.
UA46577S (uk) 1.-2. серветниця
JP1753814S (ja) ラジオ
EP4743437A1 (en) DIESTER LIPIDS, LIPID NANOPARTICLES CONTAINING DIESTER LIPIDS AND ASSOCIATED FORMULATIONS
UA46209S (uk) 1. національна сорочка
ES1254199Y (es) Identificador de medicamentos.
CL2021001674S1 (es) Vaporizador.
UA46550S (uk) 1.-2. шампур